{"641959":{"#nid":"641959","#data":{"type":"external_news","title":"The Oxford Vaccine\u2019s True Efficacy Remains Uncertain","body":[{"value":"\u003Cp\u003EScott Ganz, assistant professor in the School of Public Policy, co-authored the author \u0026quot;The Oxford Vaccine\u0026rsquo;s True Efficacy Remains Uncertain,\u0026quot; published Dec. 7, 2020 in\u0026nbsp;\u003Cem\u003EThe Dispatch\u003C\/em\u003E.\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003EGanz and co-authors Kieran Allsop and James C. Capretta provide deeper examination of the Covid-19 vaccine developed by the University of Oxford and AstraZeneca, which currently sits behind other vaccine candidates in its proximity to the market.\u003C\/p\u003E\r\n\r\n\u003Cp\u003EExcerpt:\u003C\/p\u003E\r\n\r\n\u003Cblockquote\u003E\r\n\u003Cp\u003EThe preliminary results from the Oxford-AstraZeneca Phase III trial provided cause for optimism, but left many questions unanswered. While reporting an overall vaccine efficacy rate of 70 percent\u0026mdash;a rate that exceeds the minimum 50 percent threshold set by the\u0026nbsp;\u003Ca href=\u0022https:\/\/www.who.int\/publications\/i\/item\/an-international-randomised-trial-of-candidate-vaccines-against-covid-19\u0022\u003EWorld Health O\u003C\/a\u003Erganization (WHO) and\u0026nbsp;\u003Ca href=\u0022https:\/\/www.fda.gov\/media\/139638\/download\u0022\u003EFDA\u003C\/a\u003E\u0026nbsp;for approving COVID-19 vaccines\u0026mdash;the trial sponsors further announced that the efficacy of their vaccine was 90 percent for a limited subset of participants who received a half dose and then a full dose one month apart.\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003EJust under 1 in 4 participants in the vaccine arm of the trial received the half-dose\/full-dose regimen, which was the result of a manufacturing error and not a part of the original trial protocol. The rest, 3 out 4 trial volunteers in the vaccine arm, received two full doses one month apart.\u0026nbsp;\u003C\/p\u003E\r\n\u003C\/blockquote\u003E\r\n\r\n\u003Cp\u003E\u003Ca href=\u0022https:\/\/thedispatch.com\/p\/the-oxford-vaccines-true-efficacy\u0022\u003EFull article.\u003C\/a\u003E\u003C\/p\u003E\r\n","summary":null,"format":"limited_html"}],"field_subtitle":"","field_summary":"","field_summary_sentence":"","uid":"35266","created_gmt":"2020-12-08 20:02:33","changed_gmt":"2020-12-09 15:22:13","author":"ifrazer3","boilerplate_text":"","field_publication":"","publication":"Oluwaseun (Seun) Sangodoyin","field_article_url":"","publication_url":"https:\/\/thedispatch.com\/p\/the-oxford-vaccines-true-efficacy","dateline":{"date":"2020-12-08T00:00:00-05:00","iso_date":"2020-12-08T00:00:00-05:00","tz":"America\/New_York"},"extras":[],"hg_media":{"563261":{"id":"563261","type":"image","title":"Scott Ganz","body":null,"created":"1471362057","gmt_created":"2016-08-16 15:40:57","changed":"1475895367","gmt_changed":"2016-10-08 02:56:07","alt":"Scott Ganz","file":{"fid":"206819","name":"scott-ganz.jpg","image_path":"\/sites\/default\/files\/images\/scott-ganz.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/scott-ganz.jpg","mime":"image\/jpeg","size":31907,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/scott-ganz.jpg?itok=BZ7Od1qO"}}},"media_ids":["563261"],"groups":[{"id":"1281","name":"Ivan Allen College of Liberal Arts"},{"id":"1289","name":"School of Public Policy"}],"categories":[],"keywords":[{"id":"167078","name":"School of Public Policy"},{"id":"1616","name":"Ivan Allen College of Liberal Arts"}],"core_research_areas":[],"news_room_topics":[],"event_categories":[],"invited_audience":[],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[],"email":[],"slides":[],"orientation":[],"userdata":""}}}